Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Muscle Nerve. 2015 Aug 13;52(5):887–890. doi: 10.1002/mus.24781

Increased Frequency of Rhabdomyolysis in Familial Dysautonomia

Jose-Alberto Palma 1, Ricardo Roda 2, Lucy Norcliffe-Kaufmann 1, Horacio Kaufmann 1
PMCID: PMC4596763  NIHMSID: NIHMS710960  PMID: 26202308

Abstract

Background

Familial dysautonomia (FD, OMIM# 223900) is an autosomal recessive disease featured by impaired pain and temperature perception and lack of functional muscle spindles. After 3 FD patients presented with rhabdomyolysis in a short time span, we aimed to determine the frequency of rhabdomyolysis is this population.

Methods and Results

In a retrospective chart review of 665 FD patients, 8 patients had at least 1 episode of rhabdomyolysis. Two patients had 2 episodes. The average incidence of rhabdomyolysis in FD was 7.5 per 10,000 person-years. By comparison, the average incidence with statins has been reported to be 0.44 per 10,000 person-years. Mean maximum creatine kinase (CK) level was 32,714 ± 64,749 U/l. Three patients had a hip magnetic resonance imaging showing gluteal hyperintensities.

Conclusions

Patients with FD have an increased incidence of rhabdomyolysis. We hypothesize that this may result from a combination of absent functional muscle spindles and muscle mitochondrial abnormalities.

Keywords: Autonomic disorders, Creatine kinase, Mitochondria, Skeletal muscle, Hereditary sensory autonomic neuropathy

INTRODUCTION

Familial dysautonomia (FD, Riley–Day syndrome, hereditary sensory and autonomic neuropathy type III, OMIM# 223900) is an autosomal recessive disease1 due to mutations in the IkB kinase-associated protein gene (IKBKAP).2 Mutations cause reductions of the protein product, IkB Kinase-associated protein/Elongator protein1 (IKAP/ELP-1)3, which impairs development and maintenance of sensory and autonomic neurons. Skeletal muscle is also affected4. Hallmarks include impaired pain and temperature perception, afferent baroreflex failure, chronic lung disease, absent deep tendon reflexes, gait ataxia, and lack of functional muscle spindles, all of which contribute to morbidity and mortality5.

Three of the FD patients we follow routinely in our clinic presented over a short time with episodes of rhabdomyolysis. We aimed to determine whether patients with FD have increased propensity toward developing rhabdomyolysis.

METHODS

We performed an Institutional Review Board-approved retrospective search using the New York University Dysautonomia Center database, an international registry of FD patients. The database has information on 669 FD patients worldwide, gathered longitudinally either during the visits (most FD patients come to our center for at least 1 annual evaluation) or from local doctors who send reports and/or test results. Rhabdomyolysis was defined as a creatine kinase (CK) level > 1,000 U/l6. We also studied the baseline CK value of 21 FD patients obtained during regular follow-up visits (i.e., outside rhabdomyolysis episodes).

An annual incidence rate was calculated according the formula d/y*10,000, where d is the number of rhabdomyolysis cases, and y is the number of people at risk (number of subjects * observation period).

RESULTS

Of the 665 registered patients, 8 had at least 1 episode of rhabdomyolysis. Two patients had 2 episodes. Table 1 summarizes the patient characteristics. All were receiving fludrocortisone (dosages 0.05-0.2 mg/day) for orthostatic hypotension7. Except in 2 patients who had fever during the event, body temperature was normal. Mean age at event was 20.4 ± 6.3 years. Mean maximum CK level was 32,714 ± 64,749 U/l. Mean sodium during the episode was 140 mEq/L (range: 140-150 mEq/L); mean potassium was 4 mEq/L (range: 3.9-5 mEq/L). Myoglobinuria was not determined. Four patients (patients 1, 2, 3 and 5) had a hip magnetic resonance imaging showing hyperintensities, edema and/or fluid infiltration in gluteal muscles (Supplementary Figure S1, available online). The most common triggers were prolonged immobilization due to dysautonomic crisis or pneumonia in 4 patients, fever in 2 patients, and unknown in 2 patients. Except for 1 patient (who received at-home aggressive hydration), all were hospitalized and received intravenous fluids. All recovered without further complications.

Table 1.

Characteristic of patients with familial dysautonomia and rhabdomyolysis

Patient Gender Age at
event
Medications at
event
Symptoms Maximum
CK
Presumed trigger
1 M 23 Fludrocortisone
Diazepam
Pain in left gluteal
area
25,000 Prolonged
immobilization during
dysautonomic crisis
25 Fludrocortisone
Diazepam
Pain in left gluteal
area
200,000 Prolonged
immobilization during
dysautonomic crisis
2 W 26 Fludrocortisone
Diazepam
Ranitidine
Pain in posterior
thighs
49,655 Prolonged
immobilization during
dysautonomic crisis
3 W 20 Fludrocortisone
Ranitidine
Clonidine
Pain in right
gluteal area
6,000 1-night
polysomnographic
study
23 Fludrocortisone
Ranitidine
Clonidine
Swelling and pain
in right gluteal
area
6,500 Sleeping in a hotel with
tight sheets
4 M 17 Fludrocortisone
Ranitidine
Clonidine
Carbidopa
Swelling and pain
over the left
gluteal area
4,630 Unknown
5 W 30 Midodrine
Fludrocortisone
Clonidine
Pain in left gluteal
area
1,290 Fever
6 M 18 Fludrocortisone Pain in right thigh 3,508 Prolonged
immobilization during
pneumonia
7 M 16 Fludrocortisone
Diazepam
Clonidine
Midodrine
Pregabalin
Asymptomatic 2,696 Unknown
8 M 9 Fludrocortisone
Midodrine
Clonidine
Carbidopa
Gabapentin
Weakness and
pain in
posterolateral
thighs
1,643 Fever due to viral
infection

CK: Creatine kinase.

Based on these results we calculated an annual incidence of rhabdomyolysis in FD of 7.5 per 10,000 person-years.

The mean baseline CK in 21 patients with FD (11 men, aged 23 ± 12.3) obtained during their regular follow-up visits was normal at 85.6±43.35 U/l (range: 22-159)8. One had a CK slightly below normal, but none had an elevated baseline CK level.

DISCUSSION

These findings show an increased incidence of rhabdomyolysis in patients with FD. The annual incidence rate of rhabdomyolysis in FD was 7.5 per 10,000 person-years. By comparison, the rate in patients on statins has been reported to be 0.449. This emphasizes the apparent high risk for rhabdomyolysis in FD patients, despite normal baseline CK levels. It is conceivable that an FD patient may have had an undiagnosed episode of rhabdomyolysis or that patients or local doctors may have had failed to communicate a possible case. In this case, the frequency of rhabdomyolysis would be higher, thus emphasizing its relevance in FD.

None of the medications that patients were taking has been linked consistently to rhabdomyolysis. Interestingly, in 7 out of the 10 reported cases, muscle pain was a feature of rhabdomyolysis. Although patients with FD have impaired pain sensation, this indicates that deep muscle pain is preserved.

There are several possible causes for this predisposition to rhabdomyolysis. First, impaired pain sensation might have contributed to decreased mobility during prolonged recumbency. However, rhabdomyolysis has not been reported in other genetic neuropathies with sensory impairment, such as hereditary sensory autonomic neuropathy type IV (HSAN IV). In keeping with this, in a retrospective review of 64 patients with HSAN IV in our database, some of them recently reported10, none had rhabdomyolysis.

Muscle spindles prevent over-stretching and muscle fiber damage12. Absence of functional muscle spindles in FD11 may contribute to inadvertent muscle stretching during prolonged recumbency and lead to muscle damage.

Finally, it is also possible that FD patients may have a primary muscle dysfunction. Neuromuscular manifestations of FD have been poorly described. A case report found nemaline rods in the muscle biopsy of a patient with FD, possibly due to chronic denervation13. In this regard, we have reported that FD patients have a specific type of optic neuropathy similar to other hereditary mitochondrial optic neuropathies14,15. This raises the possibility that the mutation in FD affects mitochondrial protein synthesis either in the nervous system or other organs, such as skeletal muscle.

Mitochondrial function has not been studied thoroughly in FD. Cultured FD fibroblasts disclosed no mitochondrial dysfunction16. On the other hand, in a retrospective review of our database, we found a 14-year-old FD boy in whom activity of complex I, III, and IV mitochondrial enzymes in muscle were decreased, suggesting an electron transport chain disorder. Mitochondrial DNA analysis disclosed no mutations. Mitochondrial complex dysfunction has been associated with rhabdomyolysis17, although this was not the case in this patient. Conditions such as dysautonomic crises, fever, and infections may also represent a more demanding metabolic state, which unmasks an underlying mitochondrial problem.

In conclusion, FD patients have increased incidence of rhabdomyolysis. Outside of these episodes, baseline CK is normal. We hypothesize that this may result from a combination of absent functional muscle spindles and muscle abnormalities, perhaps related to mitochondrial dysfunction. Further studies are needed to confirm this.

Supplementary Material

Legend to suppl figure
Supplemental Figure

Acknowledgments

We tank Dr. Felicia Axelrod for her dedication to the care of these patients, sharing her clinical experience, and advice. We also thank Ms. Laurie Goldberger for her help diagnosing two cases. This work was supported by the Dysautonomia Foundation Inc. and the National Institutes of Health (U54NS065736 and 1U01NS078025-01).

ABBREVIATIONS

FD

Familial dysautonomia

CK

Creatine kinase

HSAN IV

Hereditary sensory and autonomic neuropathy type IV

Footnotes

Competing interests: None.

REFERENCES

  • 1.Riley CM, Day RL. Central autonomic dysfunction with defective lacrimation; report of five cases. Pediatrics. 1949;3(4):468–478. [PubMed] [Google Scholar]
  • 2.Blumenfeld A, Slaugenhaupt SA, Axelrod FB, Lucente DE, Maayan C, Liebert CB, et al. Localization of the gene for familial dysautonomia on chromosome 9 and definition of DNA markers for genetic diagnosis. Nat Genet. 1993;4(2):160–164. doi: 10.1038/ng0693-160. [DOI] [PubMed] [Google Scholar]
  • 3.Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, Cuajungco MP, et al. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet. 2001;68(3):598–605. doi: 10.1086/318810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mezey E, Parmalee A, Szalayova I, Gill SP, Cuajungco MP, Leyne M, et al. Of splice and men: what does the distribution of IKAP mRNA in the rat tell us about the pathogenesis of familial dysautonomia? Brain Res. 2003;983(1-2):209–214. doi: 10.1016/s0006-8993(03)03090-7. [DOI] [PubMed] [Google Scholar]
  • 5.Norcliffe-Kaufmann L, Kaufmann H. Familial dysautonomia (Riley-Day syndrome): When baroreceptor feedback fails. Auton Neurosci. 2012;172(1-2):26–30. doi: 10.1016/j.autneu.2012.10.012. [DOI] [PubMed] [Google Scholar]
  • 6.Bagley WH, Yang H, Shah KH. Rhabdomyolysis. Intern Emerg Med. 2007;2(3):210–218. doi: 10.1007/s11739-007-0060-8. [DOI] [PubMed] [Google Scholar]
  • 7.Palma JA, Norcliffe-Kaufmann L, Fuente-Mora C, Percival L, Mendoza-Santiesteban C, Kaufmann H. Current treatments in familial dysautonomia. Expert Opin Pharmacother. 2014;15(18):2653–71. doi: 10.1517/14656566.2014.970530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Soldin SJ, Murthy JN, Agarwalla PK, Ojeifo O, Chea J. Pediatric reference ranges for creatine kinase, CKMB, Troponin I, iron, and cortisol. Clin Biochem. 1999;32(1):77–80. doi: 10.1016/s0009-9120(98)00084-8. [DOI] [PubMed] [Google Scholar]
  • 9.Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585–2590. doi: 10.1001/jama.292.21.2585. [DOI] [PubMed] [Google Scholar]
  • 10.Norcliffe-Kaufmann L, Katz SD, Axelrod F, Kaufmann H. Norepinephrine deficiency with normal blood pressure control in congenital insensitivity to pain with anhidrosis. Ann Neurol. 2015;77(5):743–52. doi: 10.1002/ana.24377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Macefield VG, Norcliffe-Kaufmann L, Gutierrez J, Axelrod FB, Kaufmann H. Can loss of muscle spindle afferents explain the ataxic gait in Riley-Day syndrome? Brain. 2011;134:3198–3208. doi: 10.1093/brain/awr168. Pt 11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Kakuda N, Nagaoka M. Dynamic response of human muscle spindle afferents to stretch during voluntary contraction. J Physiol. 1998;513:621–628. doi: 10.1111/j.1469-7793.1998.621bb.x. Pt 2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Amir N, Chemke J, Shapira Y. Familial dysautonomia manifesting as neonatal nemaline myopathy. Pediatr Neurol. 1985;1(4):249–251. doi: 10.1016/s0887-8994(85)80011-4. [DOI] [PubMed] [Google Scholar]
  • 14.Mendoza-Santiesteban CE, Hedges TR, 3rd, Norcliffe-Kaufmann L, Warren F, Reddy S, Axelrod FB, et al. Clinical neuro-ophthalmic findings in familial dysautonomia. J Neuroophthalmol. 2012;32(1):23–26. doi: 10.1097/WNO.0b013e318230feab. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Mendoza-Santiesteban CE, Hedges Iii TR, Norcliffe-Kaufmann L, Axelrod F, Kaufmann H. Selective retinal ganglion cell loss in familial dysautonomia. J Neurol. 2014;261(4):702–709. doi: 10.1007/s00415-014-7258-2. [DOI] [PubMed] [Google Scholar]
  • 16.Strasberg P, Bridge P, Merante F, Yeger H, Pereira J. Normal mitochondrial DNA and respiratory chain activity in familial dysautonomia fibroblasts. Biochem Mol Med. 1996;59(1):20–27. doi: 10.1006/bmme.1996.0059. [DOI] [PubMed] [Google Scholar]
  • 17.Micheletti MV, Lavoratti G, Gasperini S, Donati MA, Pela I. Hemolytic uremic syndrome and rhabdomyolysis in a patient with succinate coenzyme Q reductase (complex II) deficiency. Clin Nephrol. 2011;76(1):68–73. doi: 10.5414/cn106681. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Legend to suppl figure
Supplemental Figure

RESOURCES